Gilead Sciences, Inc.

+0.06 (+0.08%)
7:59:31 PM EDT: $70.80 +0.07 (+0.10%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)88.11B
Current PE192.81
Forward PE 18.76
2yr Forward PE 9.85
See more stats
Estimates Current Quarter
Revenue$6.69 Billion
Adjusted EPS$1.59
See more estimates
10-Day MA$66.67
50-Day MA$65.26
200-Day MA$72.44
See more pivots

Gilead Sciences, Inc. Stock, NASDAQ:GILD

333 Lakeside Drive, Foster City, California 94404
United States of America
Phone: +1.650.574.3000
Number of Employees: 18000


Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.